Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Outperform to Market Perform. Analyst Price Forecast Suggests 90.32% Upside As of April 2 ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Currently, there is only one U.S. government-approved treatment available for fatty liver disease, Rezdiffra (resmetirom), ...

This paper explores innovations in HVAC (Heating, Ventilation, and Air Conditioning) systems, highlighting the shift toward sustainable and eco-efficient solutions, with an emphasis on renewable ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Explore how stem cells transform when switching energy sources, leading to enhanced abilities and potential in regenerative ...

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...